Herbal pills and walking: a new weight loss combo?
NCT ID NCT07083947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether two herbal supplements, CL19183 and CL24212, can help overweight adults lose weight and improve their health. About 150 healthy but overweight people (BMI 25-30) aged 25-55 will take the supplements or a placebo, plus walk 30 minutes daily and follow a standard diet. The main goal is to see if body weight drops into a normal range.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
150 people
The number who actually took part.
- Started
-
Jul 2025
- Expected to finish
-
Jan 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * 1\. Healthy male and female subjects aged between 25-55 years with body mass index (BMI) of 25-29.9 kg/m2. 2\. Subjects with sedentary lifestyle, no regular athletic or sports activities. 3. Subjects willing to participate in walking-exercise (5 days a week, 30 min per day) over study duration. 4\. Subjects with normal thyroid hormone profile. 5. Subjects agreed to consume recommended standard diet. 6. Subjects who are willing to abstain from alcohol, coffee, tea, cola, energy drinks \& chocolate for at least 24 hrs. prior to visits and final visit. 7\. Subjects who are non-smokers. 8. Subject agrees to maintain diet tracker. 9. Subject considered generally healthy as per health history and routine clinical investigations during screening. 10\. Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera®, or double-barrier and have a negative pregnancy test at the screening visit. 11\. Ability to understand the risks/benefits of the protocol and willing to sign the written informed consent. Exclusion Criteria: * 1\. Subjects who were taking medications which affect the metabolic rate (e.g. antidepressants, beta-blockers, hormones, etc.). 2\. Subjects on weight loss practices, usage of weight reduction supplements/nutrition products will be excluded. 3\. Subjects underwent treatment for COVID 19 within last 3 months or tested positive during the study will be excluded. 4\. Subjects participated in any weight loss programs within 3 months. 5. Subjects who are diabetic and/or hypertensive. 6. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic diseases, malignancies. 7\. Subjects taking medications for or suffering from a medical condition that could impact results related to metabolism (e.g., thyroid disorders, diabetes, mental disorders such as anxiety or depression, heart disease, arthritis, cancer). 8\. Subjects with HIV Positive. 9. Female subjects, who are pregnant, breast feeding or planning to become pregnant during the study. 10\. Subjects having history of psychiatric disorder that may impair the ability of subjects to provide written informed consent. 11\. Any other condition that, in the opinion of the investigator, would adversely affect the subject's ability to complete the study or its measures. 12\. Use of nutritional supplements (e.g., creatine, protein drinks, amino acids, or vitamins) or ergogenic aids and caffeinated and not caffeinated thermogenics within 30 days prior to the study. 13\. Subjects who are participated or currently participating in another clinical trial within 30 days prior to screening.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy participants are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Swaroop Rani Hospital, Motilal Nehru Medical College
Allahābād, Uttar Pradesh, 211002, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does it matter where you inject? scientists test Weight-Loss drug in arm, thigh, and belly
- New drug RO7830698 put to the test for COPD
- Three pill versions of one drug go head to head in the bloodstream
- Pfizer tests RSV vaccine aimed at older adults
- Radioactive tracer maps where a new drug goes in the body
- Radioactive tag lets scientists follow an experimental drug through the human body